Skip to main content

Chimeric Antigen Receptors (CARs) for Advanced Therapies

Objective

Chimeric antigen receptors (CARs) are artificial surface receptors that can be introduced into somatic cells by genetic engineering and that act as recognition molecules like antibodies or T-cell receptors. In this respect, CARs are increasingly used for cellular therapy to redirect T-cells specifically towards killing of cancer cells. Recent success stories of cancer therapy with CAR modified T-cells have raised enormous scientific and public expectations to cure severely ill patients. However, there are still many obstacles to overcome for translation into clinics because the technology for GMP-compliant manufacture of genetically modified cellular products is extremely complex and expensive. Moreover, CAR therapy needs to be improved with respect to off-target activity, safety and potency. Consequently, the envisaged project is overall aiming at a particular technological breakthrough in cellular cancer therapy by delivering a comprehensive CARAT platform explicitly tailored for automated, easy-to-handle and cost-efficient manufacture of CAR-modified ATMP. Specifically, we aim:

(a) to implement unique next-generation cell processing tools like the CliniMACS Prodigy
(b) to develop advanced enabling technologies to obtain more effective and safer cellular products by improved gene delivery and innovative CARs design
(c) to assemble tools and technologies towards an integrated CARAT process for automated GMP-compliant manufacture of gene-modified T-cells
(d) to demonstrate proof-of-concept and regulatory compliance
(e) to disseminate broadly applicable, simplified CAR T-cell technologies

In summary, our vision is to overcome current hurdles for translation of cellular therapies and to elevate them to the next level of standard-of-care thus serving patients with so far incurable solid tumours and hematologic malignancies. Thereby, we will empower Europe to become a global leader in the development and commercialisation of CAR T-cell tools and technologies.

Field of science

  • /natural sciences/computer and information sciences/software/application software
  • /medical and health sciences/medical biotechnology/genetic engineering/gene therapy
  • /medical and health sciences/clinical medicine/cancer
  • /medical and health sciences/medical biotechnology/cells technologies

Call for proposal

H2020-PHC-2015-two-stage
See other projects for this call

Funding Scheme

RIA - Research and Innovation action
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

MILTENYI BIOTEC BV & CO KG
Address
Friedrich Ebert Strasse 68
51429 Bergisch Gladbach
Germany
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 171 913,75

Participants (8)

OSPEDALE SAN RAFFAELE SRL
Italy
EU contribution
€ 913 300
Address
Via Olgettina 60
20132 Milano
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL
Germany
EU contribution
€ 715 533,75
Address
Paul-ehrlich-strasse 51-59
63225 Langen
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France
EU contribution
€ 646 770
Address
Rue De Tolbiac 101
75654 Paris
Activity type
Research Organisations
UNIVERSITY COLLEGE LONDON
United Kingdom
EU contribution
€ 660 398,75
Address
Gower Street
WC1E 6BT London
Activity type
Higher or Secondary Education Establishments
TRAKCEL LIMITED
United Kingdom
EU contribution
€ 422 750
Address
10/11 Raleigh Walk Brigantine Place
CF10 4LN Cardiff
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
UNIVERSITAETSKLINIKUM FREIBURG
Germany
EU contribution
€ 718 580
Address
Hugstetter Strasse 49
79106 Freiburg
Activity type
Higher or Secondary Education Establishments
EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH
Germany
EU contribution
€ 561 087,50
Address
Heinrich-hertz-allee 1
66386 St Ingbert
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
MILTENYI BIOTEC GMBH

Participation ended

Germany
EU contribution
€ 1 178 825
Address
Friedrich Ebert Strasse 68
51429 Bergish Gladbach
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)